ライフサイエンスコーパス: autoimmune

1 eep rise in immune-mediated diseases such as autoimmune, allergic and chronic inflammatory disorders.

2 nhancers in mice, we show that the prominent autoimmune and allergic disease risk locus at chromosome

3 al immune cells, and aetiological origins of autoimmune and allergic diseases.

4 s into primary immunodeficiencies, inherited autoimmune and autoinflammatory diseases, and hematologi

5 In addition, they are elevated in autoimmune and autoinflammatory diseases, and in these s

6 e as important immunomodulatory cytokines in autoimmune and autoinflammatory diseases.

7 range of serious human conditions, including autoimmune and cardiovascular diseases and cancer.

8 cid sensors mediate the pathogenesis of many autoimmune and inflammatory conditions.

9 thway and the use of JAK inhibitors to treat autoimmune and inflammatory diseases across medical subs

10 d classical pathways contributes to multiple autoimmune and inflammatory diseases and overexpression

11 Autoimmune and inflammatory diseases are common and dive

12 e interaction for modulating TCR activity in autoimmune and inflammatory diseases.

13 rant OX40 cosignaling has been implicated in autoimmune and inflammatory disorders.

14 such as rheumatic diseases, as well as other autoimmune and inflammatory disorders.

15 ors to treat infectious disease, cancer, and autoimmune and inflammatory disorders.

16 roneous STING activation can exacerbate many autoimmune and inflammatory syndromes.

17 ses, including cancer and neurodegenerative, autoimmune, and metabolic diseases.

18 crobiota and in susceptibility to metabolic, autoimmune, and neoplastic diseases.

19 to hypofunctional NMDARs: schizophrenia and autoimmune anti-NMDAR encephalitis.

20 Malaria-induced anemia is related to autoimmune antibodies against the membrane lipid phospha

21 frequently characterized by the presence of autoimmune anticitrullinated protein antibodies (ACPA) d

22 K/BxN transgenic mouse develops spontaneous autoimmune arthritis with joint remodeling and profound

23 tibody formation, and mitigates experimental autoimmune arthritis.

24 regulate the activity of T cells and prevent autoimmune attack.

25 Autoimmune beta-cell destruction leads to type 1 diabete

26 to be a pivotal factor for initiation of the autoimmune blistering disease pemphigus.

27 Celiac disease is an autoimmune condition characterized by an inappropriate i

28 cally relevant antagonists used for treating autoimmune conditions can be converted into potent Fcgam

29 y been approved for the treatment of several autoimmune conditions in adults and children.

30 Adult patients with autoimmune conditions requiring immunosuppressive treatm

31 F is a potential target in many inflammatory/autoimmune conditions.

32 Autoimmune connective tissue diseases arise in a stepwis

33 patients with CSU and linked to features of autoimmune CSU.

34 ost hematopoietic cell transplantation (HCT) autoimmune cytopenia (AIC) is a potentially life-threate

35 as humoral deficiency (up to 17.6-fold) and autoimmune cytopenias (up to 12-fold).

36 Vitiligo is a complex disease in which autoimmune destruction of epidermal melanocytes results

37 a single-cell atlas defining the staging of autoimmune diabetes and reveals that diabetic autoimmuni

38 ve role for central memory CD8(+) T cells in autoimmune diabetes and that this protection is enhanced

39 n of diverse islet-infiltrating cells during autoimmune diabetes in the nonobese diabetic mouse.

40 l infections and retards effector T cells in autoimmune diabetes.

41 a-cell destruction during the development of autoimmune diabetes.

42 tio [OR], 6.30; P = .020), family history of autoimmune disease (OR, 5.12; P = .002), extra-intestina

43 lead to more effective T(reg) therapies for autoimmune disease and cancer.

44 h genes found in GWAS of MDD disease status, autoimmune disease and inflammation, and co-localized wi

45 d leukocyte counts and increased presence of autoimmune disease and positive autoantibodies.

46 mmune tolerance that are critical to prevent autoimmune disease and promote an anti-inflammatory tiss

47 roliter aOR = 1.54 [95% CI = 1.21-1.97]; and autoimmune disease aOR = 1.68 [95% CI = 1.36-2.07]).

48 iated genetic susceptibility translates into autoimmune disease are not fully understood.

49 Psoriasis is a T helper type 17 autoimmune disease associated with an increased risk car

50 Myasthenia gravis (MG) is a neuromuscular, autoimmune disease caused by autoantibodies that target

51 ic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by antinuclear antibodi

52 disorders (NMOSD) are a type of neurological autoimmune disease characterized by attacks of CNS infla

53 Type 1 diabetes is an autoimmune disease characterized by progressive loss of

54 ematosus (SLE) is a clinically heterogeneous autoimmune disease characterized by the development of a

55 genetic loci and increased susceptibility to autoimmune disease have been well characterized, however

56 lls, played a key role in the development of autoimmune disease in the central nervous system.

57 Tollip(-/-) also ameliorates STING-mediated autoimmune disease in Trex1(-/-) mice.

58 Myasthenia gravis (MG) is an autoimmune disease in which Abs target neuromuscular jun

59 Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease in which the insulin-producing beta c

60 erences suggesting distinct mechanisms drive autoimmune disease kinetics.

61 Type 1 diabetes (T1D) is an autoimmune disease of insulin-producing beta-cells.

62 Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS),

63 Multiple sclerosis (MS) is a chronic autoimmune disease of the CNS that is characterized by d

64 We then evaluated autoimmune disease parameters, kidney disease, and respo

65 Type 1 diabetes is an autoimmune disease resulting in severely impaired insuli

66 mmune cells with highly selective effects on autoimmune disease risk at the cell-subtype level.

67 into two subgroups according to concomitant autoimmune disease status.

68 the most severe organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE).

69 The autoimmune disease systemic sclerosis (SSc) causes micro

70 Type 1 diabetes (T1D)-an autoimmune disease that destroys the pancreatic islets,

71 Graves' disease (GD) is an autoimmune disease that primarily affects the thyroid gl

72 nt of at least 150 cells per microliter, and autoimmune disease were associated with frequent AECRS w

73 rythematosus (SLE) is a multisystem, chronic autoimmune disease where treatment varies by patient and

74 Neuromyelitis Optica (NMO) is an autoimmune disease with a higher prevalence in non-Europ

75 ks HLA alleles associated with high risk for autoimmune disease with ICI-induced T1D and colitis.

76 R) for SCAD among patients with a history of autoimmune disease, adjusting for race and body mass ind

77 sence of extraocular involvement, history of autoimmune disease, and durations of follow-up.

78 ombocytopenia, eczema, recurrent infections, autoimmune disease, and malignancy.

79 g recognition of the importance of GM-CSF in autoimmune disease, it remains unclear how GM-CSF is reg

80 st high salt diets have been shown to worsen autoimmune disease, the immunological consequences of cl

81 nt of at least 150 cells per microliter, and autoimmune disease, were evaluated for associations betw

82 e types of chronic inflammation ranging from autoimmune disease, which attacks specific tissues, to a

83 pMHCII-based nanomedicines displaying liver autoimmune disease-relevant yet ubiquitously expressed a

84 ng autoantigen-experienced CD4+ T cells into autoimmune disease-suppressing T regulatory type 1 (TR1)

85 he drivers of systemic abnormalities such as autoimmune disease.

86 ties involving the cardiovascular system and autoimmune disease.

87 gulation may contribute to susceptibility to autoimmune disease.

88 of self-reactive effector T cells to induce autoimmune disease.

89 atherosclerosis, cytokine storm, and chronic autoimmune disease.

90 , which is implicated in the pathogenesis of autoimmune disease.

91 nces in subclass balance are associated with autoimmune disease.

92 igher significant association with premorbid autoimmune diseases (adjusted OR 1.39 [1.28-1.50]).

93 ted a significant association with premorbid autoimmune diseases (adjusted OR 2.02 [1.72-2.49] and 1.

94 play important roles in the pathogenesis of autoimmune diseases (such as arthritis, multiple scleros

95 lity complex II-associated susceptibility to autoimmune diseases acuminates in a proinflammatory IgG

96 t at an IVIg mechanism of action in treating autoimmune diseases and allosensitization by acceleratin

97 xt of peripheral tolerance, transplantation, autoimmune diseases and cancer.

98 Th17 cells are critical drivers of autoimmune diseases and immunopathology.

99 Autoimmune diseases are a result of the immune system be

100 Tissue-specific autoimmune diseases are driven by activation of diverse

101 genesis is noninflammatory and screening for autoimmune diseases based on SCAD alone is not warranted

102 ee biosensor is developed for diagnostics of autoimmune diseases by highly sensitive measuring in hum

103 i35-Bregs suppress central nervous system autoimmune diseases by inducing infectious tolerance whe

104 ng the association between CRS and premorbid autoimmune diseases by using the National Health Insuran

105 The study of familial autoimmune diseases can reveal pathophysiological mechan

106 Autoimmune diseases comprise a spectrum of illnesses and

107 ficant association between CRS and premorbid autoimmune diseases has been identified.

108 ) fimbriae from Escherichia coli can inhibit autoimmune diseases in murine models by inducing bystand

109 at the dysregulation of the immune system in autoimmune diseases is associated with a skewing of the

110 the potential of PAD inhibition for treating autoimmune diseases like type 1 diabetes.

111 ular mechanism contributing to the polygenic autoimmune diseases of systemic lupus erythematosus and

112 erstanding the role played by lymphocytes in autoimmune diseases of the central nervous system.

113 oneuropathy (CIDP) consists of a spectrum of autoimmune diseases of the peripheral nerves, causing we

114 nuclease 1 (TREX1) cause a spectrum of human autoimmune diseases resembling systemic lupus erythemato

115 nges in the immune system, especially during autoimmune diseases such as Multiple Sclerosis (MS).

116 They are clinically beneficial in autoimmune diseases such as multiple sclerosis.

117 odies cause inflammation and organ damage in autoimmune diseases such as systemic lupus erythematosus

118 However, their role in autoimmune diseases such as systemic lupus erythematosus

119 and the accelerated atherosclerosis in many autoimmune diseases suggest that targeting inflammation

120 For instance, the autoimmune diseases systemic lupus erythematosus (SLE) a

121 cer, asthma, allergy, neurodegeneration, and autoimmune diseases they have gained attention as target

122 esvirus reactivation and subsequent onset of autoimmune diseases(1-4).

123 Among patients with concomitant autoimmune diseases, a lower proportion of patients in t

124 full analysis set stratified by concomitant autoimmune diseases, among patients without concomitant

125 treatment of subsets of lymphomas as well as autoimmune diseases, and there is a need for suitable co

126 range of infections, antitumor surveillance, autoimmune diseases, and tissue homeostasis.

127 ew criteria for comprehensive diagnostics of autoimmune diseases, based not only on traditional measu

128 of depression is higher in individuals with autoimmune diseases, but the mechanisms underlying the o

129 and several of the aaRSs have been linked to autoimmune diseases, cancer, and neurological disorders.

130 upus Erythematosus (SLE) is the prototype of autoimmune diseases, characterized by extensive gene exp

131 of endosomal TLR7 and TLR8 occurs in several autoimmune diseases, in particular systemic lupus erythe

132 an unmet clinical need for the treatment of autoimmune diseases, including multiple sclerosis (MS).

133 The effectiveness of FcRn inhibitors in autoimmune diseases, including myasthenia gravis and imm

134 to promote immune tolerance in patients with autoimmune diseases, including type 1 diabetes.

135 ty that they can be beneficial in countering autoimmune diseases, such as type 1 diabetes.

136 diseases, among patients without concomitant autoimmune diseases, three (9%) of 34 patients in the to

137 ctors play a key role in the pathogenesis of autoimmune diseases, whereas the disease-causing variant

138 tribution of each major metabolic pathway to autoimmune diseases, with a focus on systemic lupus eryt

139 lytic subunit (DNA-PKcs) are associated with autoimmune diseases, yet how DNA-PK deficiency leads to

140 reased in mice and humans with infections or autoimmune diseases.

141 e search for effective treatment of systemic autoimmune diseases.

142 ssue degradation in chronic inflammatory and autoimmune diseases.

143 s NR to more effectively treat patients with autoimmune diseases.

144 might be problematic, such as in people with autoimmune diseases.

145 hways have been linked to the development of autoimmune diseases.

146 potential therapeutic agents for cancers and autoimmune diseases.

147 in a much wider variety of antibody-mediated autoimmune diseases.

148 c obstructive pulmonary disease, and various autoimmune diseases.

149 evance to the treatment of B cell-associated autoimmune diseases.

150 r immunotherapy of malignant, infectious and autoimmune diseases.

151 process is an emerging strategy for managing autoimmune diseases.

152 rs to provide a mechanistic understanding of autoimmune diseases.

153 d suppressing the development or severity of autoimmune diseases.

154 e implicated in the pathogenesis of numerous autoimmune diseases.

155 underpin anti-microbial defenses and certain autoimmune diseases.

156 n important role in several inflammatory and autoimmune diseases.

157 deficiency has been associated with various autoimmune diseases.

158 ucial role in the progression to established autoimmune diseases.

159 t susceptibility to infectious, allergic and autoimmune diseases.

160 G are increasingly used for the treatment of autoimmune diseases.

161 mRNA, which is associated with inflammatory autoimmune diseases.

162 c target for the cutaneous manifestations of autoimmune diseases.

163 is a promising target for treating a host of autoimmune diseases.

164 k for the development of several cancers and autoimmune diseases.

165 c induction of antigen-specific tolerance in autoimmune diseases.

166 iological mechanisms involved in more common autoimmune diseases.

167 or cells, which are commonly dysregulated in autoimmune diseases.

168 latory subsets has met success in mitigating autoimmune diseases.

169 s (CRS) is associated with prior presence of autoimmune diseases; however, large-scale population-bas

170 with rheumatoid arthritis and other chronic autoimmune diseases; however, TNFalpha has proven to be

171 uced T reg cell proliferation, and a rampant autoimmune disorder similar in severity to that triggere

172 c lupus erythematosus (SLE) is a multi-organ autoimmune disorder with a prominent genetic component.

173 in inflammatory aortic disease, a rare human autoimmune disorder with increased levels of IL-17A.

174 In addition, the GBM is affected by acquired autoimmune disorders and metabolic diseases such as diab

175 y expressed antigens can blunt various liver autoimmune disorders in a non-disease-specific manner wi

176 Other infectious or autoimmune disorders were excluded.

177 l and is crucially involved in inflammation, autoimmune disorders, and cancer progression.

178 emerging functions in immune regulation and autoimmune disorders, and discuss the identification and

179 an established therapeutic target in myriad autoimmune disorders, but no TLR7 antagonist is availabl

180 s IL21 and IL15 contribute to development of autoimmune disorders, including celiac disease.

181 n the putative treatment of inflammatory and autoimmune disorders, including experimental autoimmune

182 rapeutic options for modulating inflammatory/autoimmune disorders.

183 at blocking this pathway exacerbates certain autoimmune disorders.

184 OM5 enhancers in asthma, eczema, thyroid and autoimmune disorders.

185 venue for the treatment of type I IFN-linked autoimmune disorders.

186 l disease, and exert pathological effects in autoimmune disorders.

187 amilial Mediterranean fever and experimental autoimmune encephalitis by targeting GSDMD.

188 Experimental autoimmune encephalitis is a mouse model of T cell-drive

189 ntibodies largely fall under the umbrella of autoimmune encephalitis.

190 Multiple sclerosis and experimental autoimmune encephalomyelitis (EAE) are inflammatory dise

191 null mice develop a more severe experimental autoimmune encephalomyelitis (EAE) course compared to wi

192 icient mice are desensitized to experimental autoimmune encephalomyelitis (EAE) induction, a model th

193 Experimental autoimmune encephalomyelitis (EAE) is a mouse disease mo

194 f B cells in the MS mouse model experimental autoimmune encephalomyelitis (EAE) is largely confined t

195 We first employed the experimental autoimmune encephalomyelitis (EAE) model and observed pr

196 g suppresses development of the experimental autoimmune encephalomyelitis (EAE) model of multiple scl

197 tes against inflammation in the experimental autoimmune encephalomyelitis (EAE) model of multiple scl

198 in vitro and in vivo using the experimental autoimmune encephalomyelitis (EAE) model of Th17 cell-dr

199 multiple sclerosis (MS) and its experimental autoimmune encephalomyelitis (EAE) models.

200 ed sepsis on the development of experimental autoimmune encephalomyelitis (EAE) was explored.

201 In female mice with experimental autoimmune encephalomyelitis (EAE), a murine model of MS

202 ut microbiome that occur during experimental autoimmune encephalomyelitis (EAE), an animal model for

203 he spinal cord leptomeninges in experimental autoimmune encephalomyelitis (EAE), an animal model of m

204 ant role in the pathogenesis of experimental autoimmune encephalomyelitis (EAE), an animal model of m

205 research using the animal model experimental autoimmune encephalomyelitis (EAE), substantial evidence

206 Using an animal model of MS, experimental autoimmune encephalomyelitis (EAE), we show here that in

207 osis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), we used intravital m

208 sclerosis in a murine model of experimental autoimmune encephalomyelitis (EAE).

209 sclerosis and its animal model, experimental autoimmune encephalomyelitis (EAE).

210 autoimmune disorders, including experimental autoimmune encephalomyelitis and sepsis in mice.

211 Similarly, in experimental autoimmune encephalomyelitis model of multiple sclerosis

212 enic function of T cells in the experimental autoimmune encephalomyelitis model.

213 Here, using experimental autoimmune encephalomyelitis, an established mouse MS mo

214 in T cells were protected from experimental autoimmune encephalomyelitis, demonstrating that this pa

215 g antigen-induced arthritis and experimental autoimmune encephalomyelitis, indicating that NKG2D is a

216 isease progression in experimental models of autoimmune encephalomyelitis-, SOD1(G93A) and rotenone m

217 nfers heightened sensitivity to experimental autoimmune encephalomyelitis.

218 played a profound resistance to experimental autoimmune encephalomyelitis.

219 tly suppress the MS mouse model experimental autoimmune encephalomyelitis.

220 and Aicardi-Goutieres syndrome, a hereditary autoimmune encephalopathy.

221 aneous spleen rupture, or to cure refractory autoimmune haemolytic anemia.

222 mediated cytotoxicity in in vitro models for autoimmune hemolytic anemia and antibody-mediated reject

223 ocytes in various liver pathologies, such as autoimmune hepatitis and alcoholic hepatitis.

224 efinite AIH" under the revised International Autoimmune Hepatitis Group (IAIHG) scoring system.

225 wo (<1%) patients in the atezolizumab group (autoimmune hepatitis related to atezolizumab [n=1] and s

226 ver diseases, including alcoholic hepatitis, autoimmune hepatitis, and primary biliary cirrhosis.

227 nts (irAEs), immune toxicities thought to be autoimmune in origin.

228 elease from neutrophils, the main drivers of autoimmune inflammation in this model.

229 ediator of antimicrobial immunity as well as autoimmune inflammation.

230 thogenesis of various human diseases-notably autoimmune, inflammatory and infectious diseases-and ide

231 vation, responses implicated in a variety of autoimmune, inflammatory, and transplant disease setting

232 od and Drug Administration-approved in a few autoimmune/inflammatory disorders and are being evaluate

233 ary cholangitis (PBC), a chronic cholestatic autoimmune liver disease, and the peripheral immune syst

234 These genes were enriched fourfold within autoimmune loci.

235 inically significant immunodeficiency and an autoimmune lymphoproliferative syndrome with marked pred

236 nd viral infections and (to a lesser extent) autoimmune manifestations.

237 rom five unrelated families with early onset autoimmune manifestations.

238 proliferative GN and implicate an underlying autoimmune mechanism in most cases.

239 the spinal cord or the brain and discuss the autoimmune mechanisms of complement-mediated myopathies,

240 We consider autoimmune mechanisms, central and peripheral inflammato

241 lls in pancreatic islets that is mediated by autoimmune mechanisms.

242 Type 1 diabetes results from the autoimmune-mediated destruction of functional beta-cell

243 hetic therapeutics that decrease the risk of autoimmune, metabolic, neoplastic, and infectious diseas

244 GHPs are associated with autoimmune metaplastic atrophic gastritis (AMAG).

245 inal tight junctions, is highly expressed in autoimmune mice and humans and can be used to predict tr

246 inase (MuSK)-specific IgG4 autoantibodies in autoimmune myasthenia gravis (MG) are functionally monov

247 TnI-directed autoimmune myocarditis (TnI-AM), a CD4(+) T-cell-mediate

248 tion of myocardial inflammation in rats with autoimmune myocarditis and studied the expression of FR-

249 their potential to aid in the management of autoimmune myocarditis in humans, possibly including pat

250 Conclusion: In a rat model of autoimmune myocarditis, (18)F-FOL shows specific uptake

251 nduction of TnI-AM or after establishment of autoimmune myocarditis, mice were treated with the immun

252 f peripherin-reactive B lymphocyte-dependent autoimmune neuritis.

253 Our results suggest that IL-9 reduces autoimmune neuroinflammation by suppressing GM-CSF produ

254 he therapeutic value of HuR for treatment of autoimmune neuroinflammation.

255 NIFICANCE STATEMENT Multiple sclerosis is an autoimmune neuroinflammatory disorder, based on the entr

256 nents contribute to the pathogenesis of some autoimmune neurological disorders and could even contrib

257 ome (GBS) and Fisher syndrome (FS) are acute autoimmune neuropathies, often preceded by an infection.

258 stand how these networks are dysregulated in autoimmune or inflammatory disease.

259 regulation is commonly seen in patients with autoimmune or inflammatory disorders.

260 immune retinopathy in patients without other autoimmune or malignant disease processes.

261 group of hepatobiliary diseases of probable autoimmune origin that are usually asymptomatic in the i

262 PGN amplifies autoimmune pathology via activation of innate immune cel

263 and its consequences in CD4(+) T cell-driven autoimmune pathology.

264 This spontaneous autoimmune phenotype was recapitulated in mice lacking b

265 We showed that TRAF3 deficiency-associated autoimmune phenotypes can be rectified by limiting BCR r

266 fically in thymic epithelial cells exhibited autoimmune phenotypes, including T cell infiltration.

267 nction Aire mutants, including those causing autoimmune polyendocrine syndrome type-1, form foci with

268 A large number of American patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dys

269 oinflammatory phenotypes in the skin of both autoimmune polyendocrinopathy-candidiasis-ectodermal dys

270 dead Ikkalpha knockin mice and patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dys

271 erall, our findings are not supportive of an autoimmune process as a cause of sDM in adult dogs.

272 C reactions are dispensable for T1D, but the autoimmune process in the NOD model retains pathogenic T

273 ciated with a reduction in expression of the autoimmune regulator (Aire), a critical mediator of cent

274 llary thymic epithelial cells expressing the autoimmune regulator were detected within 10 days of gen

275 roteasome-deficient strains showed mitigated autoimmune-related cardiac pathology with less inflammat

276 clerosis and suggest an initially protective autoimmune response against apoB with a progressive dera

277 cells, and potentially initiate a persistent autoimmune response against the heart.

278 s in RA as both promoters and targets of the autoimmune response, as well as discussing the mechanist

279 t muscle degeneration due to an uncontrolled autoimmune response; however, the mechanisms leading to

280 It has become increasingly appreciated that autoimmune responses against neuronal components play an

281 nce for this mechanism and the role of these autoimmune responses in various liver diseases, includin

282 By reversing heart-specific autoimmune responses, immunoproteasome inhibitors applie

283 Autoimmune responses, which are documented frequently in

284 e differentiation and function of T cells in autoimmune responses.

285 uld be considered as a potential etiology of autoimmune retinopathy in patients without other autoimm

286 esting were concerning for hereditary versus autoimmune retinopathy.

287 ously been shown to have an association with autoimmune retinopathy.

288 Organ fibrosis is a lethal outcome of autoimmune rheumatic diseases such as systemic sclerosis

289 Genetic studies have revealed that autoimmune susceptibility variants are over-represented

290 ne tolerance, as their loss leads to a fatal autoimmune syndrome in mice and humans.

291 unexpected mixed phenotype of apoB-reactive autoimmune T cells in atherosclerosis and suggest an ini

292 d as a potential target for the treatment of autoimmune T1D.

293 Here, we carried out NMR analysis of a human autoimmune TCR (MS2-3C8) that recognizes a self-peptide

294 cal studies have linked an increased risk of autoimmune thyroiditis, Graves disease and goitre to low

295 NA probes) in lymphoid, colorectal tumor and autoimmune tissues by using the nCounter system and 1,41

296 ant and potentially causal associations with autoimmune type 1 diabetes (T1D).

297 D19-STAT3KO mice develop severe experimental autoimmune uveitis (EAU), an animal model of human uveit

298 provide therapeutic benefit in experimental autoimmune uveitis (EAU).

299 Autoimmune uveitis is a sight-threatening intraocular in

300 rated decreased retinal thickness in chronic autoimmune uveitis mice, and electroretinography showed